8:30 am Online Networking


Grab a quick cup of tea or coffee from the comfort of your own home office and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

8:55 am Chair’s Opening Remarks

Developing RNA Editing Technologies in Preclinical Models

9:00 am Emergence of Novel A-to-I RNA Editing Sites


• How RNA editing sites are born?
• Reviewing how small and large scale genomic alterations lead to the formation and elimination of editing sites
• Understanding linage specific editing

9:30 am A-to-I RNA Editing in Cardiovascular Disease


• Assessing how the expression of ADARs increases in the diseased hearts compared to the healthy ones, which contributes to the increased A-to-I RNA editing sites
• Adar1 has important functions in developing hearts by controlling cardiomyocyte survival and proliferation
• The cardiomyocyte-specific deletion of Adar1 in adult murine hearts causes upregulation of genes coding for structural proteins, increases myocyte apoptosis, and worsens heart function partially due to mitochondrial dysfunction

10:00 am Online Networking & Scientific Poster Session


Grab a quick cup of tea or coffee and take a look at the virtual poster hall to learn more about the up and coming advancements in 2020. You will be able to ask the presenter questions and view their poster presentation.

Evaluating Delivery Mechanisms

11:00 am Novel AAV Capsid Engineering for Delivery of RNA-Targeted Payloads & Beyond: the ShapeTX AAVidTM Directed Evolution Platform

Identifying the Clinical Application of RNA Editing

11:30 am RNA Editing in Cancer: Functional Consequences and Therapeutic Potentials

  • Polly Leilei Chen Principle Investigator and Assistant Professor, National University of Singapore

12:00 pm Online Networking Lunch

1:00 pm How ADAR1 can drive Disease Progression by Acting Both as an RNA Editor of Specific Transcripts & as a DNA Mutator of their Cognate Genes

  • Nina Papavasiliou University Professor and Division Head
    German Cancer Research Center, Heidelberg, Germany, Visiting Professor
    Rockefeller University, New York


• Evaluating RNA editing vs DNA mutation in cancer
• (Some) deaminases can act as RNA editors and DNA mutators
• Exploiting dual function enzymes for therapeutic purposes

1:30 pm Quantification of Ongoing APOBEC3A Activity in Tumor Cells by Monitoring RNA Editing at Hotspots

  • Remi Buisson Assistant Professor, University of California Irvine


• Identifying hotspot RNA mutations in APOBEC3A-positive tumors
• Sharing how we developed a droplet digital PCR assay to quantify the RNA-editing activity of APOBEC3A
• Demonstrating that the RNA mutation-based APOBEC3A assay is applicable to clinical samples from cancer patients

2:00 pm Online Networking Break


This is your last opportunity to meet with other attendees and share virtual business cards!

2:30 pm Path to Translating Natural RNA Editing into New Possibilities for Patients; Non-Clinical & Clinical Considerations

  • Yong Chang Senior Vice President of Development, Korro Bio


• Overview of development considerations including safety, regulatory and CMC
• Application and potential early indications

3:00 pm Leveraging Advanced Virtual High Throughput Ligand Screening to Identify an ADAR1 Antagonist

  • Jamie Rice Principal Investigator , Silicon Therapeutics


  • ADAR1 inhibition targets tumor cell growth and increases anti-tumor immunity
  • Asymmetric ADAR1 dimer formation presents a unique drug target
  • Virtual High Throughput Ligand Screening (vHTS) as an ADAR1 antagonist hit finding strategy

3:30 pm Chair’s Closing Remarks & End of Conference